Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in patients with Sézary syndrome at ASH 2023
Innate Pharma To Host Virtual Kol Event On Lacutamab
Innate Pharma reports third quarter 2023 financial results and business update
Innate Pharma announces new clinical data for lacutamab and SAR443579/IPH6101 at ASH 2023
Innate Pharma announces abstracts selected for ESMO congress 2023
Innate Pharma provides update on lacutamab clinical program
Innate Pharma announces encore presentation of interim results of Phase 2 TELLOMAK study with lacutamab with updated Olsen 2022 criteria at the EORTC cutaneous lymphoma tumour group annual meeting 2023
Innate Pharma Reports First Half 2023 Financial Results And Business Update
First patient dosed in SAR’514 / IPH6401 Phase 1/2 clinical trial in relapsed/refractory multiple myeloma
First patient dosed in Phase 2 MATISSE trial of IPH5201 in early stage lung cancer
